←
Mark Bicket, MD, PhD, FASA187 posts
Mark Bicket, MD, PhD, FASA avatar

Mark Bicket, MD, PhD, FASA

@MarkBicket

Health Leader, Physician Anesthesiologist, Clinical Investigator @UMichAnesthesia • Working to improve #pain care and patient outcomes • Husband, Dad, #GoBlue

◷ Joined June 2009▧ 43 Photos and videos
Journal of the American College of Surgeons (JACS) avatar
⟳ Mark Bicket, MD, PhD, FASA retweeted
Journal of the American College of Surgeons (JACS)@acsJACS·Sep 24

More than 1 in 4 elective operation patients reported high-risk substance use before operation. In this cross-sectional study of 2,688 adults, 27.6% reported high-risk use of at least one substance and 6.6% reported high-risk polysubstance use. Read the full study by Fernandez and colleagues at: ovid.com/10.1097/XCS.0000000… @AddictionCareMI @waljeejenn @MarkBicket

0:09
Jenna Lee, MD avatar
⟳ Mark Bicket, MD, PhD, FASA retweeted
Jenna Lee, MD@jennalee1792·May 28

Freshly published protocol for our ongoing randomized controlled trial with @LKelley_Quon @HOPE_sci_lab @ChildrensLA @umichmedicine @MarkBicket Comparing Analgesic Regimen Effectiveness and Safety after surgery trial for Kids (CARES for Kids) @BMJ_Open bmjopen.bmj.com/content/16/5…

Annals of Surgery Open avatar
⟳ Mark Bicket, MD, PhD, FASA retweeted
Annals of Surgery Open@AnnalsOpen·Feb 26

Risky alcohol use can increase post-operative complications, yet pre-operative alcohol screening is inconsistent. @MarkBicket's group found AUDIT-C is a feasible screening tool that could help identify at-risk patients if integrated system-wide. doi.org/10.1097/AS9.00000000…

ASRA Pain Medicine avatar
⟳ Mark Bicket, MD, PhD, FASA retweeted
ASRA Pain Medicine@ASRA_Society·17 Sep 2025

⏰ Time is running out to save on #ASRAFALL25 registration! Sign up by Thursday, September 18 to take advantage of discounted rates for the upcoming meeting in Austin, TX. We can't wait to see you all soon! asra.com/pain

Post attachment
Mark Bicket, MD, PhD, FASA avatar
Mark Bicket, MD, PhD, FASA@MarkBicket·27 Aug 2025

Many thanks to Brian Bateman at @stanfordanes for collaborating on this piece Citation: Bicket MC, Bateman BT. Long-Term Opioid Therapy for Pain: What Is Known About Harms—and Still Not Known About Benefits. JAMA. Published online August 27, 2025. doi:10.1001/jama.2025.13225 [11/11]

Mark Bicket, MD, PhD, FASA avatar
Mark Bicket, MD, PhD, FASA@MarkBicket·27 Aug 2025

The takeaway: Prescription opioid harms are higher than we thought. But without robust data on benefits, risk mitigation will always be incomplete. What’s the first step toward balanced, safe, and compassionate opioid policy and pain care? 👇 [10/11]

Mark Bicket, MD, PhD, FASA avatar
Mark Bicket, MD, PhD, FASA@MarkBicket·27 Aug 2025

Read the full @JAMA_current commentary: 👉 jamanetwork.com/journals/jam… How should @US_FDA, clinicians, and patients respond? Join the discussion—rigorous data should guide the next phase of opioid policy. [9/11]

Mark Bicket, MD, PhD, FASA avatar
Mark Bicket, MD, PhD, FASA@MarkBicket·27 Aug 2025

Clinicians are left in limbo. They have detailed risk data—but still lack comparable evidence on long-term benefit. It’s like reading only one side of the story [8/11]

Mark Bicket, MD, PhD, FASA avatar
Mark Bicket, MD, PhD, FASA@MarkBicket·27 Aug 2025

Patients are caught in the middle. 1 in 5 long-term users faces elevated addiction risk— yet many share stories of meaningful relief that helps them function. Both matter. [7/11]

Mark Bicket, MD, PhD, FASA avatar
Mark Bicket, MD, PhD, FASA@MarkBicket·27 Aug 2025

FDA recently called for updated opioid labeling: fda.gov/news-events/press-an… That’s movement—but only half the problem. We also must avoid reflexive de-prescribing & forced tapers, which carry risks of mental health harms, suicide, & even death. [6/11]

Mark Bicket, MD, PhD, FASA avatar
Mark Bicket, MD, PhD, FASA@MarkBicket·27 Aug 2025

Would you be surprised to know these data come from studies run by opioid manufacturers—under FDA oversight? Here’s the real catch: the focus has been on harms, with far less progress on whether opioids provide long-term benefit. Docs: fda.gov/advisory-committees/… [5/11]

Mark Bicket, MD, PhD, FASA avatar
Mark Bicket, MD, PhD, FASA@MarkBicket·27 Aug 2025

New data from FDA-required studies: -> 20% report misuse within 1 year of long-term use -> 27% of long-acting users meet OUD criteria -> Overdose: up to 4% within 5 years The burden is larger than most realized. [4/11]

Post attachment
Mark Bicket, MD, PhD, FASA avatar
Mark Bicket, MD, PhD, FASA@MarkBicket·27 Aug 2025

Prescribing has plummeted since 2012: -> Long-acting prescriptions fell 41% (22.8M → 9.3M) -> Short-acting fell 49% 📉 The sharpest declines in 3 decades—yet harms remain stubbornly high. [3/11]

Post attachment